Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir
Alimentary Pharmacology & Therapeutics · 2024
DOI: 10.1111/apt.18020 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2024. Verfasst von Juan Carlos Ruiz-Cobo und 28 weiteren Autor:innen. Beteiligte Einrichtung: Universitat Autònoma de Barcelona (UAB), Barcelona, Spain. Hauptthemen laut MEDLINE: Hepatitis C, Chronic, Heterocyclic Compounds, 4 or More Rings, Antiviral Agents, Sofosbuvir. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Sofosbuvir, velpatasvir and voxilaprevir (SOF/VEL/VOX) is the recommended rescue therapy for patients with chronic hepatitis C infection who fail direct‐acting antivirals (DAAs). Data are limited on the effectiveness of this treatment after the current first‐line therapies. Our aim was to analyse the effectiveness and safety of SOF/VEL/VOX among patients failing sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB).
Methods
Retrospective multicentre study (26 Spanish hospitals), including chronic hepatitis C patients unsuccessfully treated with SOF/VEL or GLE/PIB, and retreated with SOF/VEL/VOX ± ribavirin for 12 weeks between December 2017 and December 2022.
Results
In total, 142 patients included: 100 (70.4%) had failed SOF/VEL and 42 (29.6%) GLE/PIB. Patients were mainly men (84.5%), White (93.9%), with hepatitis C virus genotype (GT) 3 (49.6%) and 47.2% had liver cirrhosis. Sustained virological response (SVR) was evaluated in 132 patients who completed SOF/VEL/VOX and were followed 12 weeks after end of treatment; 117 (88.6%) achieved SVR. There were no significant differences in SVR rates according to initial DAA treatment (SOF/VEL 87.9% vs. GLE/PIB 90.2%, p = 0.8), cirrhosis (no cirrhosis 90% vs. cirrhosis 87.1%, p = 0.6) or GT3 infection (non‐GT3 91.9% vs. GT3 85.5%, p = 0.3). However, when considering the concurrent presence of SOF/VEL treatment, cirrhosis and GT3 infection, SVR rates dropped to 82.8%. Ribavirin was added in 8 (6%) patients, all achieved SVR.
Conclusion
SOF/VEL/VOX is an effective rescue therapy for failures to SOF/VEL or GLE/PIB, with an SVR of 88.6%. Factors previously linked to lower SVR rates, such as GT3 infection, cirrhosis and first‐line therapy with SOF/VEL were not associated with lower SVRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
- Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
- Liver Unit, Hospital Clínic, Barcelona, Spain.
- Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi i Sunyer (FRCB-IDIBAPS), Barcelona, Spain.
- University of Barcelona (UB), Barcelona, Spain.
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain.
ORCID-Profile: Juan Carlos Ruiz-Cobo, Jordi Llaneras, Xavier Forns, Adolfo Gallego Moya, Isabel Conde Amiel, Ana Arencibia, Moises Diago, Javier García-Samaniego, Jose Castellote, Susana Llerena, Beatriz Mateos, Manuel Rodríguez, Jose Miguel Rosales Zabal, Jose Luis Calleja, Rosa María Morillas, Silvia Montoliu, Raul J Andrade, Ester Badia Aranda, Manuel Hernández-Guerra, Jesús M González-Santiago, Vanesa Bernal-Monterde, Juan Turnes, Sabela Lens, María Buti
Zitieren
APA
Ruiz-Cobo, J. C., Llaneras, J., Forns, X., Gallego Moya, A., Conde Amiel, I., Arencibia, A., Diago, M., García-Samaniego, J., Castellote, J., Llerena, S., Rodríguez-Seguel, E., Mateos, B., Rodríguez, M., Rosales Zabal, J. M., Fernández, I., Calleja, J. L., Morillas, R. M., Montoliu, S., Andrade, R. J., …, & Buti, M. (2024). Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.18020
Vancouver
Ruiz-Cobo JC, Llaneras J, Forns X, Gallego Moya A, Conde Amiel I, Arencibia A, et al. Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir. Alimentary Pharmacology & Therapeutics. 2024. doi:10.1111/apt.18020
BibTeX
@article{RuizCobo2024,
author = {Ruiz-Cobo, Juan Carlos and Llaneras, Jordi and Forns, Xavier and Gallego Moya, Adolfo and Conde Amiel, Isabel and Arencibia, Ana and Diago, Moises and García-Samaniego, Javier and Castellote, Jose and Llerena, Susana and Rodríguez-Seguel, Elisa and Mateos, Beatriz and Rodríguez, Manuel and Rosales Zabal, Jose Miguel and Fernández, Inmaculada and Calleja, Jose Luis and Morillas, Rosa María and Montoliu, Silvia and Andrade, Raul J and Badia Aranda, Ester and Hernández-Guerra, Manuel and Maté, Carlota Jimeno and González-Santiago, Jesús M and de Cuenca, Beatriz and Bernal-Monterde, Vanesa and Delgado, Manuel and Turnes, Juan and Lens, Sabela and Buti, María},
title = {Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
doi = {10.1111/apt.18020}
}
EUVIMED